Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients : lessons from early variant infection and impact on shaping emerging variants
Serological studies of COVID-19 convalescent patients have identified polyclonal lineage-specific and cross-reactive antibodies (Abs), with varying effector functions against virus variants. Individual specificities of anti-SARS-CoV-2 Abs and their impact on infectivity by other variants have been little investigated to date. Here, we dissected at a monoclonal level neutralizing and enhancing Abs elicited by early variants and how they affect infectivity of emerging variants. B cells from 13 convalescent patients originally infected by D614G or Alpha variants were immortalized to isolate 445 naturally-produced anti-SARS-CoV-2 Abs. Monoclonal antibodies (mAbs) were tested for their abilities to impact the cytopathic effect of D614G, Delta, and Omicron (BA.1) variants. Ninety-eight exhibited robust neutralization against at least one of the three variant types, while 309 showed minimal or no impact on infectivity. Thirty-eight mAbs enhanced infectivity of SARS-CoV-2. Infection with D614G/Alpha variants generated variant-specific (65 neutralizing Abs, 35 enhancing Abs) and cross-reactive (18 neutralizing Abs, 3 enhancing Abs) mAbs. Interestingly, among the neutralizing mAbs with cross-reactivity restricted to two of the three variants tested, none demonstrated specific neutralization of the Delta and Omicron variants. In contrast, cross-reactive mAbs enhancing infectivity (n = 3) were found exclusively specific to Delta and Omicron variants. Notably, two mAbs that amplified in vitro the cytopathic effect of the Delta variant also exhibited neutralization against Omicron. These findings shed light on functional diversity of cross-reactive Abs generated during SARS-CoV-2 infection and illustrate how the balance between neutralizing and enhancing Abs facilitate variant emergence.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Emerging microbes & infections - 13(2024), 1 vom: 02. Feb., Seite 2307510 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Coutant, Frédéric [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 01.02.2024 Date Revised 02.02.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/22221751.2024.2307510 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367307480 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367307480 | ||
| 003 | DE-627 | ||
| 005 | 20240202232147.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240119s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2024.2307510 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM367307480 | ||
| 035 | |a (NLM)38240255 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Coutant, Frédéric |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients |b lessons from early variant infection and impact on shaping emerging variants |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.02.2024 | ||
| 500 | |a Date Revised 02.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Serological studies of COVID-19 convalescent patients have identified polyclonal lineage-specific and cross-reactive antibodies (Abs), with varying effector functions against virus variants. Individual specificities of anti-SARS-CoV-2 Abs and their impact on infectivity by other variants have been little investigated to date. Here, we dissected at a monoclonal level neutralizing and enhancing Abs elicited by early variants and how they affect infectivity of emerging variants. B cells from 13 convalescent patients originally infected by D614G or Alpha variants were immortalized to isolate 445 naturally-produced anti-SARS-CoV-2 Abs. Monoclonal antibodies (mAbs) were tested for their abilities to impact the cytopathic effect of D614G, Delta, and Omicron (BA.1) variants. Ninety-eight exhibited robust neutralization against at least one of the three variant types, while 309 showed minimal or no impact on infectivity. Thirty-eight mAbs enhanced infectivity of SARS-CoV-2. Infection with D614G/Alpha variants generated variant-specific (65 neutralizing Abs, 35 enhancing Abs) and cross-reactive (18 neutralizing Abs, 3 enhancing Abs) mAbs. Interestingly, among the neutralizing mAbs with cross-reactivity restricted to two of the three variants tested, none demonstrated specific neutralization of the Delta and Omicron variants. In contrast, cross-reactive mAbs enhancing infectivity (n = 3) were found exclusively specific to Delta and Omicron variants. Notably, two mAbs that amplified in vitro the cytopathic effect of the Delta variant also exhibited neutralization against Omicron. These findings shed light on functional diversity of cross-reactive Abs generated during SARS-CoV-2 infection and illustrate how the balance between neutralizing and enhancing Abs facilitate variant emergence | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a B cell repertoire | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a antibody-dependent enhancement | |
| 650 | 4 | |a emerging variants | |
| 650 | 4 | |a human monoclonal antibody | |
| 650 | 7 | |a Antibodies, Blocking |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Touret, Franck |e verfasserin |4 aut | |
| 700 | 1 | |a Pin, Jean-Jacques |e verfasserin |4 aut | |
| 700 | 1 | |a Alonzo, Marina |e verfasserin |4 aut | |
| 700 | 1 | |a Baronti, Cécile |e verfasserin |4 aut | |
| 700 | 1 | |a Munier, Sandie |e verfasserin |4 aut | |
| 700 | 1 | |a Attia, Mikaël |e verfasserin |4 aut | |
| 700 | 1 | |a de Lamballerie, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Ferry, Tristan |e verfasserin |4 aut | |
| 700 | 1 | |a Miossec, Pierre |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging microbes & infections |d 2012 |g 13(2024), 1 vom: 02. Feb., Seite 2307510 |w (DE-627)NLM249608804 |x 2222-1751 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:1 |g day:02 |g month:02 |g pages:2307510 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/22221751.2024.2307510 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 1 |b 02 |c 02 |h 2307510 | ||